GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » bioAffinity Technologies Inc (NAS:BIAF) » Definitions » Intrinsic Value: Projected FCF

bioAffinity Technologies (bioAffinity Technologies) Intrinsic Value: Projected FCF : $0.00 (As of May. 27, 2024)


View and export this data going back to 2022. Start your Free Trial

What is bioAffinity Technologies Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-27), bioAffinity Technologies's Intrinsic Value: Projected FCF is $0.00. The stock price of bioAffinity Technologies is $2.67. Therefore, bioAffinity Technologies's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for bioAffinity Technologies's Intrinsic Value: Projected FCF or its related term are showing as below:

BIAF's Price-to-Projected-FCF is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.63
* Ranked among companies with meaningful Price-to-Projected-FCF only.

bioAffinity Technologies Intrinsic Value: Projected FCF Historical Data

The historical data trend for bioAffinity Technologies's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bioAffinity Technologies Intrinsic Value: Projected FCF Chart

bioAffinity Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - -

bioAffinity Technologies Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of bioAffinity Technologies's Intrinsic Value: Projected FCF

For the Diagnostics & Research subindustry, bioAffinity Technologies's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


bioAffinity Technologies's Price-to-Projected-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where bioAffinity Technologies's Price-to-Projected-FCF falls into.



bioAffinity Technologies Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



bioAffinity Technologies  (NAS:BIAF) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

bioAffinity Technologies's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=2.67/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


bioAffinity Technologies Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of bioAffinity Technologies's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


bioAffinity Technologies (bioAffinity Technologies) Business Description

Traded in Other Exchanges
N/A
Address
22211 W Interstate 10, Suite 1206, San Antonio, TX, USA, 78257
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.
Executives
Roby Joyce director 22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Xavier Trinidad Reveles officer: Chief Operating Officer 22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Michael Philip Dougherty officer: Chief Financial Officer 2934 SCATTERED OAKS ST, SAN ANTONIO TX 78232
James Michael Edwards officer: Chief Financial Officer 30907 KEENELAND DRIVE, FAIR OAKS RANCH TX 78015
Peter S Knight director 6702 STEIN CIRCLE, #642, P.O. BOX 4138, PARK CITY UT 84060
Steven Girgenti director, officer: Executive Chairman C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Robert A. Anderson director 70 DOPPLER, IRVINE CA 92618
Gary D Rubin director, 10 percent owner 2080 NW BOCA RATON BLVD, STE 2, BOCA RATON FL 33431
Stuart Diamond director 498 SEVENTH AVE, NEW YORK NY 10018
Maria Zannes director, officer: President, CEO 19702 BELLA LOMA, #6005, SAN ANTONIO TX 78256
Harvey Sandler Revocable Trust 10 percent owner 21170 N. E. 22ND COURT, NORTH MIAMI BEACH FL 33180
Mohsin Y Meghji director C/O LOUGHLIN MEGHJI + COMPANY, NEW YORK NY 10016
Vivienne I Rebel officer: EVP, Chief Sci. & Med. Officer 8922 APACHE TRAIL, SAN ANTONIO TX 78255
Timothy P Zannes officer: Secretary, EVP, Gen. Counsel 1510 VISTA LARGA CT. NE, ALBUQUERQUE NM 87106
Nathan M Perlmutter 10 percent owner 28 PARRISH POND LANE, SOUTHAMPTON NY 11968